Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Voysey M, Flaxman A, Aboagye J, Aley PK, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Charlton S, Clutterbuck EA, Davies S, Dold C, Edwards NJ, Ewer KJ, Faust SN, Folegatti PM, Fowler J, Gilbride C, Gilbert SC, Godfrey L, Hallis B, Humphries HE, Jenkin D, Kerridge S, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Snape MD, Song R, Thomas KM, Ulaszewska M, Woods D, Wright D, Pollard AJ, Lambe T.
Voysey M, et al. Among authors: ramasamy mn.
Clin Exp Immunol. 2023 Mar 24;211(3):280-287. doi: 10.1093/cei/uxad013.
Clin Exp Immunol. 2023.
PMID: 36729167
Free PMC article.